文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

巴瑞替尼联合标准治疗用于有创机械通气或体外膜氧合的危重型COVID-19住院成人:探索性随机安慰剂对照试验的疗效与安全性

Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2022-02-03
一句话结论危重型COVID-19需有创机械通气或ECMO者,巴瑞替尼4 mg每日一次联合标准治疗降低28天和60天全因死亡率,但属探索性小样本试验。

COV-BARRIER探索性试验在阿根廷、巴西、墨西哥和美国18家医院纳入101例基线有创机械通气或ECMO的危重型COVID-19成人,1:1随机接受巴瑞替尼4 mg或安慰剂每日一次最多14天,联合标准治疗(86%使用全身糖皮质激素)。巴瑞替尼组28天全因死亡率39%(20/51)vs 安慰剂组58%(29/50),HR 0.54(95%CI 0.31–0.96),p=0.030;60天死亡率45%(23/51)vs 62%(31/50),HR 0.56(95%CI 0.33–0.97),p=0.027。无呼吸机天数与住院时长两组无显著差异;感染、血栓和心血管不良事件发生率相似。作者认为结果与主COV-BARRIER研究中较轻患者的死亡率降低一致,但为探索性小样本试验,需进一步3期试验确认。

要点

  • 危重型COVID-19有创机械通气或ECMO成人:巴瑞替尼4 mg每日一次最多14天联合标准治疗,28天死亡20/51(39%)vs 安慰剂29/50(58%),HR 0.54(95%CI 0.31–0.96),p=0.030。
  • 60天死亡23/51(45%)vs 31/50(62%),HR 0.56(95%CI 0.33–0.97),p=0.027;28天和60天每治疗6例可额外避免1例死亡。
  • 无呼吸机天数均值8.1天(SD 10.2)vs 5.5天(SD 8.4),p=0.21,差异无统计学显著性。
  • 住院时长均值23.7天(SD 7.1)vs 26.1天(SD 3.9),p=0.050,差异无统计学显著性。
  • 感染、血栓和不良心血管事件发生率两组相似;标准治疗中86%(87例)使用全身糖皮质激素。

适用人群与场景

  • 年龄≥18岁、实验室确诊SARS-CoV-2感染、基线接受有创机械通气或体外膜氧合的危重型住院成人。
  • 研究在阿根廷、巴西、墨西哥和美国的18家医院开展;为标准3期COV-BARRIER试验未纳入的危重队列。

处置流程与药物剂量

  • 巴瑞替尼4 mg口服,每日一次,最多14天,联合标准治疗;对照为安慰剂加标准治疗。
  • 标准治疗包括基线全身糖皮质激素使用,87例(86%)使用。

研究设计与关键结果

  • 探索性、随机、双盲、安慰剂对照试验,纳入101例,巴瑞替尼组51例、安慰剂组50例;主要终点为28天和60天全因死亡率等预设终点。
  • 28天全因死亡:巴瑞替尼组20/51(39%)vs 安慰剂组29/50(58%),HR 0.54(95%CI 0.31–0.96),p=0.030;相对降低46%,绝对风险降低19%。
  • 60天全因死亡:巴瑞替尼组23/51(45%)vs 安慰剂组31/50(62%),HR 0.56(95%CI 0.33–0.97),p=0.027;相对降低44%,绝对风险降低17%。
  • 28天和60天每治疗6例巴瑞替尼组患者可额外避免1例死亡(与安慰剂相比)。
  • 无呼吸机天数:巴瑞替尼组均值8.1天(SD 10.2)vs 安慰剂组5.5天(SD 8.4),p=0.21;差异无统计学显著性。
  • 住院时长:巴瑞替尼组均值23.7天(SD 7.1)vs 安慰剂组26.1天(SD 3.9),p=0.050;差异无统计学显著性。
  • 感染、血栓和不良心血管事件发生率两组相似。
  • 研究时间为2020年12月23日至2021年4月10日。

证据类型、等级与局限

  • 证据类型:探索性、随机、双盲、安慰剂对照试验;疗效分析基于意向治疗人群,安全性分析基于安全性人群。
  • 作者结论:巴瑞替尼联合标准治疗(包括糖皮质激素)降低死亡率,与主COV-BARRIER研究中较轻患者的死亡率降低一致。
  • 局限:探索性试验,样本量相对较小;作者指出需进一步3期试验确认这些发现。

对床旁实践的改变

  • 作者认为,对于有创机械通气或ECMO的危重型COVID-19住院成人,巴瑞替尼联合标准治疗(包括糖皮质激素)可降低死亡率。
  • 作者指出本试验为探索性、样本量相对较小,需进一步3期试验确认这些发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation.

METHODS: This exploratory trial followed the study design of COV-BARRIER in a critically ill cohort not included in the main phase 3 trial. The study was conducted across 18 hospitals in Argentina, Brazil, Mexico, and the USA. Participants (aged ≥18 years) hospitalised with laboratory-confirmed SARS-CoV-2 infection on baseline invasive mechanical ventilation or extracorporeal membrane oxygenation were randomly assigned (1:1) to baricitinib (4 mg) or placebo once daily for up to 14 days in combination with standard of care. Participants, study staff, and investigators were masked to study group assignment. Prespecified endpoints included all-cause mortality through days 28 and 60, number of ventilator-free days, duration of hospitalisation, and time to recovery through day 28. The efficacy analysis was done in the intention-to-treat population and the safety analysis was done in the safety population. This trial is registered with ClinicalTrials.gov, NCT04421027.

FINDINGS: Between Dec 23, 2020, and April 10, 2021, 101 participants were enrolled into the exploratory trial and assigned to baricitinib (n=51) or placebo (n=50) plus standard of care. Standard of care included baseline systemic corticosteroid use in 87 (86%) participants. Treatment with baricitinib significantly reduced 28-day all-cause mortality compared with placebo (20 [39%] of 51 participants died in the baricitinib group vs 29 [58%] of 50 in the placebo group; hazard ratio [HR] 0·54 [95% CI 0·31-0·96]; p=0·030; 46% relative reduction; absolute risk reduction 19%). A significant reduction in 60-day mortality was also observed in the baricitinib group compared with the placebo group (23 [45%] events vs 31 [62%]; HR 0·56 [95% CI 0·33-0·97]; p=0·027; 44% relative reduction; absolute risk reduction 17%). In every six baricitinib-treated participants, one additional death was prevented compared with placebo at days 28 and 60. The number of ventilator-free days did not differ significantly between treatment groups (mean 8·1 days [SD 10·2] in the baricitinib group vs 5·5 days [8·4] in the placebo group; p=0·21). The mean duration of hospitalisation in baricitinib-treated participants was not significantly shorter than in placebo-treated participants (23·7 days [SD 7·1] vs 26·1 days [3·9]; p=0·050). The rates of infections, blood clots, and adverse cardiovascular events were similar between treatment groups.

INTERPRETATION: In critically ill hospitalised patients with COVID-19 who were receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, treatment with baricitinib compared with placebo (in combination with standard of care, including corticosteroids) reduced mortality, which is consistent with the mortality reduction observed in less severely ill patients in the hospitalised primary COV-BARRIER study population. However, this was an exploratory trial with a relatively small sample size; therefore, further phase 3 trials are needed to confirm these findings.

FUNDING: Eli Lilly and Company.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

参考来源

  1. Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022. PMID: 35123660. doi:10.1016/S2213-2600(22)00006-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。